Conflict of interest: Nothing to report
Continuing Medical Education Program in American Journal of Hematology
Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management†
Article first published online: 18 MAY 2011
Copyright © 2011 Wiley-Liss, Inc.
American Journal of Hematology
Volume 86, Issue 6, pages 490–498, June 2011
How to Cite
Garcia-Manero, G. (2011), Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management. Am. J. Hematol., 86: 490–498. doi: 10.1002/ajh.22047
- Issue published online: 18 MAY 2011
- Article first published online: 18 MAY 2011
- Manuscript Accepted: 29 MAR 2011
- Manuscript Received: 28 MAR 2011
The myelodysplastic (MDS) are a very heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and increased risk of transformation to acute myelogenous leukemia (AML). MDS occurs more frequently in older male and in individuals with prior exposure to cytotoxic therapy.
Diagnosis of MDS is based on morphological evidence of dysplasia upon visual examination of a bone marrow aspirate and biopsy. Information obtained from additional studies such as karyotype, flow cytometry, or molecular genetics is complementary but not diagnostic.
Prognosis of patients with MDS can be calculated using a number of scoring systems. In general, all these scoring systems include analysis of peripheral cytopenias, percentage of blasts in the bone marrow, and cytogenetic characteristics. The most commonly used system is the International Prognostic Scoring System. This score divides patients into a lower risk subset (low and intermediate-1) and a higher risk subset (int-2 and high). Other more modern systems have been developed that allow more precise risk calculation.
Therapy is selected based on risk, transfusion needs, percent of bone marrow blasts and more recently cytogenetic profile. Goals of therapy are different in lower risk patients than in higher risk. In lower risk, the goal is to decrease transfusion needs and transformation to higher risk disease or AML. In higher risk, the goal is to prolong survival. Current available therapies include growth factor support, lenalidomide, hypomethylating agents, intensive chemotherapy, and allogeneic stem cell transplantation. The use of lenalidomide has significant clinical activity in patients with lower risk disease, anemia, and a chromosome 5 alteration. 5-azacitidine and decitabine have activity in higher risk MDS. 5-azacitidine has been shown to improve survival in higher risk MDS. Additional supportive care measures may include the use of prophylactic antibiotics and iron chelation.
Management of progressive or refractory disease:
At the present time, there are no approved interventions for patients with progressive or refractory disease particularly after hypomethylating based therapy. Options include cytarabine-based therapy, transplantation, and participation on a clinical trial. Am. J. Hematol. 86:491–498, 2011. © 2011 Wiley-Liss, Inc.